The Anti-Hepatitis C Agent Nitazoxanide Induces Phosphorylation of Eukaryotic Initiation Factor 2α Via Protein Kinase Activated by Double-Stranded RNA Activation

Gastroenterology

Volumn 137, Issue 5, 2009, Pages 1827-1835

  Elazar, Menashe ^a   Liu, Michael ^a   McKenna, Sean A ^a   Liu, Ping ^a   Gehrig, Elizabeth A ^a   Puglisi, Joseph D ^a   Rossignol, Jean François ^a,b   Glenn, Jeffrey S ^a,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Romark Institute for Medical Research   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; DOUBLE STRANDED RNA; INITIATION FACTOR 2ALPHA; NITAZOXANIDE; PROTEIN KINASE INHIBITOR; PROTEIN KINASE R; THIAZOLE DERIVATIVE; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; HEPATITIS C VIRUS; HOST CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RNA REPLICATION;

ANTIPARASITIC AGENTS; ANTIVIRAL AGENTS; CELL CULTURE TECHNIQUES; CELL LINE; EIF-2 KINASE; EUKARYOTIC INITIATION FACTOR-2; HEPATITIS C; HEPATOCYTES; HUMANS; INTERFERONS; PHOSPHORYLATION; THIAZOLES;

EID: 70350125916     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.07.056     Document Type: Article

References (37)

1. Shepard C.W., Finelli L., and Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5 (2005) 558-567
2. Manns M.P., Foster G.R., Rockstroh J.K., et al. The way forward in HCV treatment-finding the right path. Nat Rev Drug Discov 6 (2007) 991-1000
3. Moradpour D., Penin F., and Rice C.M. Replication of hepatitis C virus. Nat Rev Microbiol 5 (2007) 453-463
4. Liu-Young G., and Kozal M.J. Review: hepatitis C protease and polymerase inhibitors in development. AIDS Patient Care STDS 22 (2008) 449-457
5. Tong X., Chase R., Skelton A., et al. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 70 (2006) 28-38
6. He Y., Duan W., and Tan S.L. Emerging host cell targets for hepatitis C therapy. Drug Discov Today 12 (2007) 209-217
7. Tan S.L., Ganji G., Paeper B., et al. Systems biology and the host response to viral infection. Nat Biotechnol 25 (2007) 1383-1389
8. He B. Viruses, endoplasmic reticulum stress, and interferon responses. Cell Death Differ 13 (2006) 393-403
9. Gale Jr. M., and Foy E.M. Evasion of intracellular host defence by hepatitis C virus. Nature 436 (2005) 939-945
10. Garcia M.A., Meurs E.F., and Esteban M. The dsRNA protein kinase PKR: virus and cell control. Biochimie 89 (2007) 799-811
11. Prostko C.R., Brostrom M.A., Malara E.M., et al. Phosphorylation of eukaryotic initiation factor (eIF) 2 alpha and inhibition of eIF-2B in GH3 pituitary cells by perturbants of early protein processing that induce GRP78. J Biol Chem 267 (1992) 16751-16754
12. Lu P.D., Harding H.P., and Ron D. Translation reinitiation at alternative open reading frames regulates gene expression in an integrated stress response. J Cell Biol 167 (2004) 27-33
13. Ron D., and Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 8 (2007) 519-529
14. Anderson V.R., and Curran M.P. Nitazoxanide: a review of its use in the treatment of gastrointestinal infections. Drugs 67 (2007) 1947-1967
15. Korba B.E., Montero A.B., Farrar K., et al. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res 77 (2008) 56-63
16. Rossignol J., Elfert A., El-Gohary Y., et al. Interim data from a randomized controlled trial of nitazoxanide-peginterferon-ribavirin, nitazoxanide-peginterferon and peginterferon-ribavirin in the treatment of patients with chronic hepatitis C genotype 4. Hepatology 46 (2007) 316A-317A
17. Rossignol J.F., Elfert A., El-Gohary Y., et al. Randomized controlled trial of nitazoxanide-peginterferon-ribavirin, nitazoxanide-peginterferon and peginterferon-ribavirin in the treatment of patients with chronic hepatitis C genotype 4. J Hepatol 48 (2008) S30
18. Rossignol J.F., Elfert A., El-Gohary Y., et al. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology 136 (2009) 856-862
19. Rossignol J.F., Kabil S.M., El-Gohary Y., et al. Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther 28 (2008) 574-580
20. Blight K.J., McKeating J.A., and Rice C.M. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol 76 (2002) 13001-13014
21. Blight K.J., Kolykhalov A.A., and Rice C.M. Efficient initiation of HCV RNA replication in cell culture. Science 290 (2000) 1972-1974
22. Matto M., Rice C.M., Aroeti B., et al. Hepatitis C virus core protein associates with detergent-resistant membranes distinct from classical plasma membrane rafts. J Virol 78 (2004) 12047-12053
23. Lindenbach B.D., Evans M.J., Syder A.J., et al. Complete replication of hepatitis C virus in cell culture. Science 309 (2005) 623-626
24. Sharp T.V., Xiao Q., Jeffrey I., et al. Reversal of the double-stranded-RNA-induced inhibition of protein synthesis by a catalytically inactive mutant of the protein kinase PKR. Eur J Biochem 214 (1993) 945-948
25. Sharp T.V., Xiao Q., Justesen J., et al. Regulation of the interferon-inducible protein kinase PKR and (2′-5′)oligo(adenylate) synthetase by a catalytically inactive PKR mutant through competition for double-stranded RNA binding. Eur J Biochem 230 (1995) 97-103
26. Feldman D.E., Chauhan V., and Koong A.C. The unfolded protein response: a novel component of the hypoxic stress response in tumors. Mol Cancer Res 3 (2005) 597-605
27. Fels D.R., Ye J., Segan A.T., et al. Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways. Cancer Res 68 (2008) 9323-9330
28. McKenna S.A., Lindhout D.A., Shimoike T., et al. Viral dsRNA inhibitors prevent self-association and autophosphorylation of PKR. J Mol Biol 372 (2007) 103-113
29. Hamid R., Rotshteyn Y., Rabadi L., et al. Comparison of alamar blue and MTT assays for high through-put screening. Toxicol In Vitro 18 (2004) 703-710
30. Tardif K.D., Mori K., and Siddiqui A. Hepatitis C virus subgenomic replicons induce endoplasmic reticulum stress activating an intracellular signaling pathway. J Virol 76 (2002) 7453-7459
31. Harding H.P., Zhang Y., and Ron D. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature 397 (1999) 271-274
32. Rossignol J.F., Abu-Zekry M., Hussein A., et al. Effect of nitazoxanide for treatment of severe rotavirus diarrhoea: randomised double-blind placebo-controlled trial. Lancet 368 (2006) 124-129
33. Gale Jr. M.J., Korth M.J., and Katze M.G. Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: a potential mechanism of interferon resistance. Clin Diagn Virol 10 (1998) 157-162
34. Taylor D.R., Shi S.T., Romano P.R., et al. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 285 (1999) 107-110
35. McKenna S.A., Lindhout D.A., Kim I., et al. Molecular framework for the activation of RNA-dependent protein kinase. J Biol Chem 282 (2007) 11474-11486
36. Pang P.S., Planet P.J., and Glenn J.S. The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy. PLoS One 4 (2009) e6579
37. Korba B.E., Elazar M., Lui P., et al. Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide. Antimicrob Agents Chemother 52 (2008) 4069-4071